Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study

INTRODUCTION: The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62.5 μg, and vilanterol (VI) 25 μg demonstrated a reduction in the rate of moderate or severe exa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Adv Ther
Main Authors: Tabberer, Maggie, Jones, C. Elaine, Kilbride, Sally, Halpin, David M. G., Lomas, David A., Pascoe, Steven, Singh, Dave, Wise, Robert A., Criner, Gerard J., Lange, Peter, Dransfield, Mark T., Han, MeiLan K., Martinez, Fernando J., Kaisermann, Morrys C., Lipson, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444357/
https://ncbi.nlm.nih.gov/pubmed/32647911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01409-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados